1612254-46-2

Upstream product

• 874301-22-1 2-(4-hydroxyphenyl)-3H-benzoimidazole-5-carboxylic acid N-methoxy-N-methylamide 
• 1635-61-6 5-chloro-2-nitroaniline 
• 129012-05-1 2-(4-hydroxyphenyl)-3H-benzoimidazole-5-carbaldehyde 
• 660432-02-0 N-methoxy N-methyl 3,4-diaminobenzoic acid amide 
• 391903-19-8 N-methoxy N-methyl 3,4-dinitrobenzoic acid amide 
• 528-45-0 3,4-dinitrobenzoic acid 
• 21867-64-1 1-n-propylpiperazine 
• 1612254-20-2 5-(4-allyl-1-piperazinyl)-2'-nitroacetanilide 
• 123-08-0 4-hydroxy-benzaldehyde 
• 66639-62-1 5-cyano-2-(4-hydroxyphenyl)-3H-benzimidazole 
• 17626-40-3 4-cyano-1,2-phenylenediamine 
• 5443-33-4 N-(5-chloro-2-nitrophenyl)acetamide 
• 1612254-28-0 5-(4-allyl-1-piperazinyl)-2-nitroaniline 
• 13961-36-9 1-allylpiperazine 

Relevant academic research and scientific papers

Synthesis and investigation of novel benzimidazole derivatives as antifungal agents

The rise and emergence of resistance to antifungal drugs by diverse pathogenic fungal strains have resulted in an increase in demand for new antifungal agents. Various heterocyclic scaffolds with different mechanisms of action against fungi have been investigated in the past. Herein, we report the synthesis and antifungal activities of 18 alkylated mono-, bis-, and trisbenzimidazole derivatives, their toxicities against mammalian cells, as well as their ability to induce reactive oxygen species (ROS) in yeast cells. Many of our bisbenzimidazole compounds exhibited moderate to excellent antifungal activities against all tested fungal strains, with MIC values ranging from 15.6 to 0.975?μg/mL. The fungal activity profiles of our bisbenzimidazoles were found to be dependent on alkyl chain length. Our most potent compounds were found to display equal or superior antifungal activity when compared to the currently used agents amphotericin B, fluconazole, itraconazole, posaconazole, and voriconazole against many of the strains tested.

Synthesis and biological evaluation of novel bisbenzimidazoles as Escherichia coli topoisomerase IA inhibitors and potential antibacterial agents

Novel bisbenzimidazole inhibitors of bacterial type IA topoisomerase are of interest for the development of new antibacterial agents that are impacted by target-mediated cross resistance with fluoroquinolones. The present study demonstrates the successful synthesis and evaluation of bisbenzimidazole analogues as Escherichia coli topoisomerase IA inhibitors. 5-(4-Propylpiperazin- 1-yl)-2-[2′-(4-ethoxyphenyl)-5′-benzimidazolyl]benzimidazole (12b) showed significant relaxation inhibition activity against EcTopo 1A (IC 50 = 2 ± 0.005 μM) and a tendency to chelate metal ion. Interestingly, these compounds did not show significant inhibition of E. coli DNA gyrase and hTop 1 even up to 100 μM. Compound 12b has shown lowest MIC against E. coli strains among 24 compounds evaluated. The binding affinity constant and binding free energy of 12b with EcTopo 1A was observed 6.8 × 106 M-1 and -10.84 kcal mol-1 from isothermal titration calorimetry (ITC), respectively. In vivo mouse systemic infection and neutropenic thigh model experimental results confirmed the therapeutic efficacy of 12b, suggesting further development of this class of compounds as antibacterial agents.